RAY1225
The Safety, Tolerability and Pharmacokinetic Study of RAY1225
Guangdong Raynovent Biotech Co · Phase 1 · Completed · Enrollment 68
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| RAY1225(Part A) | n/r | n/r | n/r | n/r |
| Placebo (Part A) | n/r | n/r | n/r | n/r |
| RAY1225 (Part B) | n/r | n/r | n/r | n/r |
| Placebo (Part B) | n/r | n/r | n/r | n/r |
| RAY1225(Part C) | n/r | n/r | n/r | n/r |
| Placebo (Part C) | n/r | n/r | n/r | n/r |
Not shown
- RAY1225(Part A): endpoint not reported
- Placebo (Part A): endpoint not reported
- RAY1225 (Part B): endpoint not reported
- Placebo (Part B): endpoint not reported
- RAY1225(Part C): endpoint not reported
- Placebo (Part C): endpoint not reported